Vision Through Innovation
Our mission is to develop Micro Invasive Glaucoma Surgery (MIGS) technology with the capability of restoring the natural outflow pathway of aqueous humor from the eye and make it available to the 10’s of millions of people suffering from Glaucoma – which left untreated leads to irreversible blindness
Glaucoma treatment market: present $6 Billion per year to over $9 billion per year in 2030.
Patients currently spending $1 billion per year, growing at 24% annually to $6 billion per year by 2030.
eyeFlow has taken a very successful and difficult to perform conventional glaucoma surgical procedure limited to a handful of ophthalmic surgeons and converted it into a very easy and fast Micro Invasive Glaucoma Surgery (MIGS) any ophthalmic surgeon can perform.
Micro Invasive Glaucoma Surgery (MIGS)
Revolutionary Glaucoma treatment paradigm change.
Displacing conventional Glaucoma surgery and medications.
30% CAGR - the fastest growing market in eye care.
Your support of eyeFlow empowers an opportunity to potentially save millions of people from blindness by changing treatment of the disease before it progresses.
Contact eyeFlow today for more information on its life changing technology.